Clinical trials: Anal Canal Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Anal Canal, HPV-induced Cancer
Towards an Understanding of Barriers and Delays in the Diagnosis of Anal Cancer
This study examines care pathways in 300 patients with anal squamous cell carcinoma to identify barriers and delays in diagnosis, assess the impact of screening and access to care, and improve awareness, screening practices, and…
- Trial name
- FRACAS (NCT07455942)
- Testing
- self-administered questionnaire
- Where
- 32 sites in France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Anal Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining radiation therapy with chemotherapy may kill more tumor cells.
- Trial name
- NCT00003596
- Testing
- cisplatin, fluorouracil, mitomycin C
- Where
- 485 sites in United States, South Africa
- Volunteers
- 682 people
- Sponsor
- Radiation Therapy Oncology Group
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma
Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer
This randomized phase II trial studies how well cisplatin and fluorouracil work compared with carboplatin and paclitaxel in treating patients with anal cancer that cannot be removed by surgery, has come back at or near the same…
- Conditions
- Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma
- Trial name
- InterAACT (NCT02560298)
- Testing
- Capecitabine, Carboplatin, Cisplatin
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Anal Canal Squamous Cell Carcinoma
A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer
The objective of this trial is to assess anti-tumour activity of BI 754091 as monotherapy and of BI 754091 in combination with BI 836880 in patients with unresectable or metastatic squamous cell carcinoma of the anal canal who…
- Trial name
- NCT04499352
- Testing
- BI 754091, BI 836880
- Where
- South Korea
- Sponsor
- Boehringer Ingelheim
Cancer That is Associated With a Chronic Viral Infection, p16 Positive SCCHN
Avelumab With Valproic Acid in Virus-associated Cancer
Up to 20% of all cancers may be associated with a bacterial or viral infection. In some instances, the infection may be one of the reasons why the cancer developed in the first place.
- Conditions
- Cancer That is Associated With a Chronic Viral Infection, p16 Positive SCCHN, Squamous Cell Carcinoma of the Cervix, p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva
- Trial name
- LATENT (NCT03357757)
- Testing
- Valproic Acid, Avelumab
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- AHS Cancer Control Alberta
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer
Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)
70% all cases of cervical cancer, 95% of anal cancers and about 70% of oropharyngeal cancers are linked to Human Papillomavirus (HPV) infection. HPV oncogenic proteins are trans-activators of telomerase.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer, Cervical Cancer
- Trial name
- VolATIL (NCT03946358)
- Testing
- Blood sample collection, Tumor biopsies, CT scan
- Where
- 4 sites in France
- Volunteers
- 47 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
This phase III trial investigates how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer.
- Conditions
- Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8
- Trial name
- NCT03233711
- Testing
- Biopsy Procedure, Biospecimen Collection, Colonoscopy
- Where
- 896 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- National Cancer Institute (NCI)
HPV-Related Carcinoma, Uterine Cervical Cancer
Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes
After definitive radiotherapy (RT) treatment (with or without chemotherapy), cervical and anal canal neoplasms frequently exhibit disease persistence or recurrence.
- Conditions
- HPV-Related Carcinoma, Uterine Cervical Cancer, Anal Canal Cancer, HPV-Related Anal Squamous Cell Carcinoma
- Trial name
- ANA (NCT06640283)
- Testing
- ctDNA test, Pembrolizumab
- Where
- Brazil
- Volunteers
- 150 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
HSIL, High Grade Squamous Intraepithelial Lesions, Anal Cancer
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand
The purpose of this research is to assess the safety and effectiveness of circumferential radiofrequency ablation (RFA) to the anal canal using the BarrxTM Ablation System to destroy anal high-grade squamous intraepithelial…
- Conditions
- HSIL, High Grade Squamous Intraepithelial Lesions, Anal Cancer, HPV-Related Squamous Cell Carcinoma, Human Papilloma Virus
- Trial name
- NCT03302858
- Testing
- BARRX™ Anorectal Wand
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Stephen E. Goldstone
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
This phase 3 trial compares the addition of nivolumab to chemotherapy (carboplatin and paclitaxel) versus usual treatment (chemotherapy alone) for the treatment of anal cancer that has spread to other places in the body…
- Conditions
- Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Metastatic Anal Squamous Cell Carcinoma, Recurrent Anal Squamous Cell Carcinoma
- Trial name
- NCT04444921
- Testing
- Carboplatin, Nivolumab, Paclitaxel
- Where
- 579 sites in United States
- Volunteers
- 205 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Anal Canal
An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)
To provide retifanlimab, on a reactive basis, to adult patients with squamous carcinoma of the anal canal in combination with carboplatin and paclitaxel and who are considered ineligible for other therapeutic options including…
- Trial name
- NCT06910137
- Testing
- retifanlimab
- Sponsor
- Incyte Corporation
Anal Cancer
Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00025090
- Testing
- cisplatin, fluorouracil, mitomycin C
- Where
- 13 sites in United Kingdom
- Volunteers
- 600 people
- Sponsor
- University College London (UCL) Cancer Institute